Kazia Therapeutics (KZIA) vs Rani Therapeutics (RANI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Kazia Therapeutics (KZIA) has outperformed Rani Therapeutics (RANI) over the past year, losing 41.1% versus a loss of 68.6%. Over five years, RANI leads with a -98.3% price change compared with -99.0% for KZIA. Rani Therapeutics is the larger company by market cap ($59.0 million vs $56.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KZIA | RANI |
|---|---|---|
| Share price | $4.92 | $0.5111 |
| Market cap | $56.22M | $59.03M |
| 1-day change | -8.38% | -11.97% |
| YTD return | -28.59% | -62.14% |
| 1-year return | -41.08% | -68.64% |
| 5-year return | -99.01% | -98.34% |
| EPS (TTM) | $-6.85 | $-0.06 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $1.63M |
| Revenue growth (YoY) | — | +58.85% |
| Net income (latest FY) | — | $-29.67M |
| Operating margin | — | -2345.99% |
| Net margin | — | -1817.09% |
| 52-week high | $17.40 | $1.69 |
| 52-week low | $4.50 | $0.502 |
| Distance from 52-week high | -71.72% | -69.76% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +476.02% | +1308.73% |
| Average volume | 307.30K | 545.67K |
| Shares outstanding | 11.43M | 115.49M |
| Employees | 6 | 69 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- KZIA has outperformed RANI by 27.6 percentage points over the past year.
About Kazia Therapeutics
KZIA stock →Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma; in Phase II trial to treat isocitrate dehydrogenase-mutant glioma, primary central nervous system (CNS) lymphoma, diffuse intrinsic pontine glioma, and brain metastases; and in pre-clinical studies to treat triple-negative breast cancer, as well as for the treatment of atypical rhabdoid/teratoid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 6 employees
About Rani Therapeutics
RANI stock →Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 69 employees
KZIA vs RANI FAQ
Which is bigger, Kazia Therapeutics or Rani Therapeutics?
Rani Therapeutics (RANI) is larger, with a market capitalization of $59.03M compared with $56.22M for Kazia Therapeutics (KZIA).
Which stock has performed better over the past year, KZIA or RANI?
KZIA returned -41.08% over the past 12 months, compared with -68.64% for RANI (price return, excluding dividends). Past performance does not predict future results.
Are Kazia Therapeutics and Rani Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.